Multicancer early detection testing results in extended life-years and reduced cancer treatment costs through earlier diagnosis, leading to a cost-effective option in cancer screening.
Denise Zou, MA
Advertisement
Articles by Denise Zou, MA
An economic model based on the ECHELON-2 trial demonstrated cost-effectiveness of brentuximab vedotin with chemotherapy in frontline treatment of CD30-expressing peripheral T-cell lymphoma (PTCL).
Advertisement
Latest Updated Articles
Cost-Effectiveness of a Multicancer Early Detection Test in the USDecember 13th 2024
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
3
EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”
4
Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD
5